ArticleBMJ open2022

Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.

Johnny Ludvigsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.